The effectiveness of antioxidant agents in delaying progression of diabetic nephropathy: A systematic review of randomized controlled trials

Ika Rahayu ^1,2 , Nur Arfian ^3,4 * , Christina Yeni Kustanti ^5,6 , Mae Sri Hartati Wahyuningsih ^4,7

Cited by CrossRef: 0

1- Matsui T, Sotokawauchi A, Nishino Y, Koga Y, Yamagishi S. Apixaban Inhibits Progression of Experimental Diabetic Nephropathy by Blocking Advanced Glycation End Product-Receptor Axis. IJMS. 2025;26(7):3007 [Crossref]

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate (2024): 20%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded; Google Scholar; SJR; Essential Science Indicators; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO
Member of COPE
Follower of ICMJE
Permission: Creative Commons